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Background/aim: Transcatheter aortic valve implantation (TAVI) is an innovative approach to the treatment of aortic stenosis (AS)
as an alternative to surgery in high-risk patients. Mean platelet volume (MPV) is considered an indicator of endothelial dysfunction,
platelet function, and activation. In this study, we aimed to investigate MPV changes in patients undergoing TAVI.
Materials and methods: This study included 100 patients diagnosed with symptomatic severe AS and treated with TAVI between July
2011 and August 2013. Hematological parameters of the patients were examined prior to the procedure and 24 h, 1 month, and 6 months
after TAVI.
Results: A statistically significant change in patients’ MPV was detected after TAVI compared to the baseline situation (P: 0.001). While
no statistically significant change was observed on the first day after TAVI, at discharge, compared to the baseline situation, a statistically
significant decrease was seen 1 month and 6 months after discharge.
Conclusion: We have demonstrated a decrease in MPV after surgery compared to the value before surgery. We have sought to propound
the change in MPV as an indication of endothelial function after TAVI.
Key words: Severe aortic stenosis, transcatheter aortic valve implantation, mean platelet volume

1. Introduction
Degenerative aortic stenosis (AS) is a valvular heart
disease that reduces the quality of life in patients with this
condition. The disease usually presents with exertional
dyspnea, syncope, angina, heart failure, and sudden
cardiac death, which mostly seen in elderly patients. It was
reported that prevalence of severe AS in the United States
is 2% (1). Approximately, 50% of patients die within 2 years
of the beginning of symptoms (2). Medical treatment is
usually insufficient in this group. Therefore, symptomatic
patients should be considered for aortic valve replacement
as soon as possible. Surgical aortic valve replacement
(sAVR) has been used as a gold standard treatment of
severe symptomatic AS for many years. Unfortunately, the
risk from surgery is extremely high due to elderliness or
co-morbidities and it is found that 30% of patients are not
appropriate for surgery (3–5).
Transcatheter aortic valve implantation (TAVI) is a
novel treatment option for high-risk patients with severe
AS as an alternative to sAVR. It was first performed by
* Correspondence: huseyinayhan44@yahoo.com

Cribier in 2002 (6). TAVI has become a viable method
quickly and safely, particularly with the development of
percutaneous technology.
It has been suggested that the development of AS
is an active process mediated by chronic inflammation
rather than aging. This chronic inflammatory process is
associated with atherosclerotic risk factors (7). These risk
factors are considered to be likely causes of endothelial
dysfunction and valve damage (7,8). Increased endothelial
permeability, monocyte infiltration, intimal smooth muscle
cell proliferation, and platelet aggregation are important
components of atherogenesis (9). In recent years, mean
platelet volume (MPV) was assessed as an indicator of
platelet function and activation (10,11). Increased MPV is
considered an indicator of increased risk for cardiovascular
disease in the general population. It was found that MPV is
also an indicator of atherosclerotic diseases and endothelial
dysfunction in several studies (12).
In light of this information, we aimed to research
of the impact of TAVI on MPV. We also aimed to show
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whether TAVI has positive effects on the healing aspects
of endothelial dysfunction and the effect of endothelial
dysfunction in the AS pathogenesis based on the
relationship between MPV and endothelial dysfunction.
2. Materials and methods
Between July 2011 and August 2013 one hundred
consecutive patients with symptomatic severe AS included
in this study were inoperable or high-risk for sAVR. The
symptomatic status of patients was determined according
to New York Heart Association (NYHA) classification
before the TAVI and during the follow-up visits. Patients
with aortic valve area (AVA) less than 0.8 cm2 and/or
average transvalvular gradient greater than 40 mmHg,
and/or maximal transvalvular blood flow velocity faster
than 4.0 m/s were included in the study based on severe
AS echocardiographic criteria and current guidelines. The
decision regarding TAVI was taken by consensus during
the Heart Team meeting. Informed consent was obtained
from all patients before the TAVI. Ethical approval was
provided from the ethics committee of our hospital before
the study.
Hematological parameters of patients were tested
before the procedure, 24 h after the procedure, at the
time of discharge, and after 1 and 6 months following
the procedure. White blood cell count (WBC, 103/mm3),
hemoglobin (Hg, g/dL), hematocrit value (Htc, %), platelet
count (103/mm3), and MPV (fL) were examined. Routine
physical examinations, echocardiography, laboratory
parameters, and functional capacity were evaluated during
the follow ups.
2.1. Preparation before TAVI
Aortic valve morphology, aortic annulus, the coronary
ostium–annulus distance, the degree of calcification,
peripheral arterial suitability, and additional pathologies
were assessed for all patients by transthoracic
echocardiography, Doppler and 2D images, transesophageal
echocardiography, and multislice computed tomography.
2.2. TAVI procedure
Balloon expandable Edwards Sapien and Edwards Sapien
XT (Edwards Lifesciences, Irvine, CA, USA) heart valves
were implemented in all patients via transfemoral route.
The procedures were performed under local anesthesia for
75% of patients and general anesthesia for 25%. During
the operation, intravenous heparin was used to achieve
an activated clotting time of 250–300 s. A femoral closure
device (Prostar XL 10F system, Abbott Vascular, Redwood
City, CA, USA, and Proglide, Abbott Vascular Inc.) was
used in 85% of patients and surgical closure was applied
15% of patients.
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2.3. Laboratory
Tubes containing ethylenediaminetetraacetic acid (EDTA)
for automated blood count (15% K3 EDTA 0.054 mL/3 mL
blood) were used. In the complete blood count, a Sysmex
XE-2100 automated hematology analyzer was used. In our
hospital, as a general principle, the blood is drawn with
minimal stasis from the antecubital vein into vacuum
tubes.
2.4. Statistical analysis
SPSS for Windows 21.0 was used for the assessment by
recording study data on a computer. As well as descriptive
statistical methods (mean, standard deviation), for the
comparison of quantitative data, Student’s t test for the
comparison of normally distributed parameters between
the groups and Wilcoxon’s test for the comparison of
nonnormally distributed parameters between the groups
were used. The paired sample t test was used for intragroup
comparison of the parameters. The chi-square test and
Fisher’s test were used for the comparison of qualitative
data. One-way repeated measures analysis of variance
(ANOVA) was used for the evaluation of the data obtained
at preoperation, postoperation, discharge, first month, and
sixth month. Results at 95% confidence interval, P < 0.05
significance level were assessed.
3. Results
Approximately 66% of the patients were females and
the mean age was 78.2 years. The average valve area and
mean gradient were 0.63 ± 0.17 cm2 and 52.6 ± 13.9
mmHg respectively, according to echocardiography. The
patients’ mean STS (Society of Thoracic Surgeons) score
and mean logistic EuroScore were respectively 7.3 ± 5.2
and 22.4 ± 15.9. According to the SURTAVI risk model,
90% of patients were considered middle and high risk.
The operational success rate was 100%. However, second
valve implementation was required in a patient due to low
positioning and valve embolization to the ascending aorta
occurred in another patient. The 23-mm valve was used
in 56% of patients, the 26-mm valve in 42% of patients,
and the 29-mm valve in 2% of patients. Moreover, 91% of
patients were in NYHA class III and IV, 80% of patients had
coronary artery disease, 82% of patients had hypertension,
34% of patients had peripheral arterial disease, and 27%
of patients had diabetes mellitus. Basal characteristics of
the patients and data on TAVI are given in Tables 1 and 2.
After the TAVI, 4 mortalities occurred in hospital
because of the following reasons: right ventricular
rupture due to rapid pacing in the operation (2 patients),
left ventricular rupture due to wire in the left ventricle,
and left main coronary artery obstruction caused
by calcification on the aortic cusp. Stroke was not observed
in any patient. Permanent pacemaker implantation was
performed on four patients (4%) due to atrioventricular
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Table 1. Baseline characteristics of patients.

Table 2. Echocardiographic variables and procedural features.

Characteristics

N = 100 patients

Echocardiographic variables

Male/Female (n)

34/66

Maximal gradient (mmHg)

86.3 ± 21.7

Age (years)

78.2 ± 7.2

Mean gradient (mmHg)

52.6 ± 13.9

BMI (kg/m2)

27.9 ± 7.6

AVA (cm2)

0.63 ± 0.17

NYHA II (n)

7

LVEF (%)

54 ± 14.7

NYHA III (n)

64

47.3 ± 13.3

NYHA IV (n)

29

Peak systolic pulmonary artery
pressure (mmHg)

STS score (%)

7.3 ± 5.2

SURTAVI
- low risk (n)
- mid risk (n)
- high risk (n)

10
32
58

Logistic EuroScore (%)

22.4 ± 15.9

Comorbid conditions

Aortic regurgitation (n)
Low
Moderate
Severe

59
3
1

Mitral regurgitation (n)
Low
Moderate
Severe

60
5
3

Femoral vascular closure (%)

85

Coronary artery disease (%)
- One vessel (%)
- Two vessel (%)
- Three vessel (%)

80
30
28
22

Valve diameter mm (n)
- 23
- 26
- 29

56
42
2

Hypertension (%)

82

Contrast used (cc)

201.5 ± 55.7

Diabetes mellitus (%)

27

Duration of discharge after procedure (days)

7.4 ± 5.4

Hyperlipidemia (%)

45

Smoker (%)

19

COPD (%)
- Mild
- Moderate
- Severe

46
39
23

Peripheral arterial disease (%)

34

Atrial fibrillation (%)

28

BMI; Body Mass Index, NYHA; New York Heart Association,
STS; Society of Thoracic Surgeons, COPD; Chronic Obstructive
Pulmonary Disease

block. When we look at vascular complications, hematoma
in one patient and pseudoaneurysm in one patient were
observed. Erythrocyte suspension transfusion more than
two units was applied to 16% of patients. The average
discharge time was 7.4 ± 5.4 days. During the follow
up, 2 patients died in the first month and 4 more by 6
months, making a total of 10 mortalities. At discharge after
TAVI and during the follow up, statistically significant
recovery was observed in valve functions (mean gradient,
AVA). Advanced paravalvular aortic regurgitation (AR)
developed in one patient. It was also observed that 93% of

TEE; transesophageal echocardiography, AVA; aortic valve area,
LVEF; Left ventricular ejection fraction

patients were class 1 and 2 functional capacity according
to the NYHA classification.
When we look the effects of TAVI on the hematological
parameters, pre-TAVI patients’ mean WBC counts were
7.3 ± 4.0 (103/mm3), Hg (g/dL) was 12.7 ± 1.3, Hct was 35
± 6.1 (%), platelet counts were 226.1 ± 137 (103/mm3), and
MPV was 10.7 ± 0.8 (fL). Post-TAVI at discharge, WBC
counts were 8.3 ± 6.4, Hg was 10.3 ± 1.4, Htc was 30.9 ±
4.1, platelet counts were 183.6 ± 98.4, and MPV was 10.5 ±
1.3 (Table 3). In Hg and Hct values of patients, statistically
significant changes were observed compared to before
TAVI (P < 0.001). There was a statistically significant
decrease in Hg and Hct values one day after TAVI and
at discharge but there was a statistically nonsignificant
increase in Hg and Hct values at one month and six
months and these values reached the levels they had been
before the TAVI.
There were statistically significant changes in patients’
platelet counts than before TAVI (P < 0.001). However, a
statistically significant decrease was seen in platelet counts
one day after the operation, at discharge, and at one and six
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Table 3. Changing of hematologic parameters with TAVI at follow up.
Parameters

Pre-TAVI

1 day

Discharge

1 month

6 months

P value

WBC

7.3 ± 4.0

9.4 ± 5.3

8.3 ± 6.4

7.8 ± 8.5

7.4 ± 4.8

0.275

Hg

12.7 ± 1.3

11.3 ± 4.0

10.3 ± 1.4

11.4 ± 1.6

11.9 ± 1.8

<0.001

Hct

35.0 ± 6.1

32.8 ± 6.1

30.9 ± 4.1

34.7 ± 4.9

36.3 ± 4.9

<0.001

Plt

226.1 ± 137.0

203.2 ± 152.6

183.6 ± 98.4

214.4 ± 91.2

217.4 ± 119.6

0.001

MPV

10.7 ± 0.8

10.5 ± 0.8

10.5 ± 1.3

10.3 ± 1.0

10.4 ± 1.0

0.007

WBC: White blood cells, Hg: hemoglobin, Hct: hematocrit, Plt: Platelet, MPV: Mean platelet volume

months after the TAVI, in comparison to platelet counts
before the procedure. Statistically significant changes in
MPV were also observed after the operation (P = 0.001).
No statistically significant changes were observed on the
first day or at discharge (short-term) in comparison with
preoperational conditions, whereas at one month and six
months (midterm) a statistically significant decline was
observed (Figure).
4. Discussion
In this study we observed a patient population who had
symptomatic severe AS with high risk for surgery and
performed TAVI. We then compared pre-TAVI and postTAVI MPV, which is an indicator of platelet activation
and endothelial dysfunction. We showed that the decrease

Figure. Changing of MPV after TAVI.
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in MPV after TAVI is significant in the midterm in spite
of a minor decrease in the short term, as evidence that
AS etiopathogenesis can be a generalized endothelial
dysfunction and post-TAVI endothelial dysfunction and
platelet activation can be cured.
Platelets play a key role in the development of
atherosclerosis and its acute complications. Platelet
size is an important factor for physical and chemical
functions of platelets. It is generally accepted that large
platelets are metabolically and enzymatically more active.
Large platelets contain more alpha granules and plateletderived substances and they are inclined to adhesion
and aggregation. Platelet size is also related to platelet
activation indicators such as increase in intracellular
calcium levels, synthesis of thromboxane A2, serotonin
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and β thromboglobulin release, and adhesion molecules’
expression. Increased MPV indicates larger platelet
volume, an indicator of platelet activations and functions
that is assumed as increased risk of cardiovascular disease
(9,10). Endothelial dysfunction can be summarized
as impairment of vasomotor, coagulation, fibrinolysis
functions of the vessel; change in local immunity functions;
and impairment of endothelial functions characterized by
increase in vascular proliferation. Endothelial dysfunction
plays a substantially important role in peripheral and
coronary atherosclerosis pathogenesis (13). Studies have
shown that one of the indicators of endothelial dysfunction
is MPV (14).
Previous studies have shown that platelet activation
increased due to shear stress induced by turbulence flow
in stenotic valve in AS patients. Dimitrov et al. showed that
increases in thrombin and platelet activation indicators
in AS patients are independent of coronary and carotid
atherosclerosis (15). Sucu et al. observed increases in
platelet activation indicators including MPV and PDW
in patients with aortosclerosis (16). Varol et al. showed
that MPV increased in AS patients independently of
miscellaneous risk factors (17). Bilen et al. found that MPV
increases in patients with bicuspid aortic valves (18). Varol
et al. showed increases in MPV in patients with mitral
stenosis in sinus rhythm in comparison with their control
group (19). Erdogan et al. showed significant decreases in
MPV at one month postoperation in comparison with the
preoperative period in patients who underwent balloon
valvuloplasty due to rheumatismal mitral stenosis (20).
The incidence of chronic kidney failure increases in
elderly patients with severe aortic stenosis. Previous studies
have shown that MPV is increased in chronic kidney
failure patients and it is also associated with mortality.
Keles et al. found that 51.4% of patients with severe aortic
stenosis treated with TAVR have chronic kidney failure

and the glomerular filtration rate is better following the
TAVR procedure (21).
Gul et al. observed 33 patients for 4 months; they
experienced a progressive decrease in MPV after TAVI
(22). Magri et al. showed preoperative low MPV is
associated with increased vascular complications after
transfemoral TAVI and life-threatening bleeding (23). In
our study we found 10.7 ± 0.8 fL average values for MPV in
patients before the operation. During follow up, there was
no statistically significant change in patients’ MPV at 1 day
postoperation or at discharge (short term) in comparison
with preoperation. Regarding preoperation MPV, at 1
and 6 months postoperation (midterm) a statistically
significant decrease was observed. In the literature there
is no extensive study conducted in the long term dealing
with the effects of TAVI on MPV. In addition, according
to our study, a statistically significant decrease in platelet
counts of patients was observed 1 day after TAVI in
comparison with preoperational levels. However, platelet
levels were found to increase at discharge and 1 and 6
months postoperation compared to preoperative levels.
Changes in platelet, Hg, and Hct levels are considered to
be associated with blood loss and hypervolume.
In conclusion, in developed societies, incidence of
severe AS increases continuously together with average
life expectancy. The rate of TAVI application in patients
who have high risks of sAVR rises gradually. In this
study we have demonstrated the effect of TAVI on MPV.
We propound that there is a decrease in MPV compared
with its preoperative value after TAVI. This result can
be interpreted to indicate that post-TAVI endothelial
functions may be restored and platelet activation may
decrease. Large population and randomized studies on
significance of post-TAVI change in MPV and its possible
effects on mortality are needed.
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